TRPML1 triggers ferroptosis defense and is a potential therapeutic target in AKT-hyperactivated cancer.
Zhang HL, Hu BX, Ye ZP, Li ZL, Liu S, Zhong WQ, Du T, Yang D, Mai J, Li LC, et al. Sci Transl Med. 2024 Jun 26; 16(753):eadk0330. Epub 2024 Jun 26.